Carrier‐Free Platinum Nanomedicine for Targeted Cancer Therapy

Abstract

Numerous nanomedicines have been developed to improve the efficiency and safety of conventional anticancer drugs; however, the complexities in carrier materials and functional integration make it challenging to promote these candidates for clinical translation. In this study, a facile method to prepare carrier‐free anticancer nanodrug with inherent bone targeting and osteoclastogenesis inhibition capabilities is reported. Phytic acid, a naturally occurring and nontoxic product, is reacted with cisplatin to form uniform nanoparticles of different sizes. The prepared nanoparticles possess high drug loading and pH‐responsive drug release behaviors. Phytic acid in the nanomedicine ensures high bone targeting and osteoclastogenesis inhibition, and the released platinum drugs triggered by tumor extracellular acidity eradicate tumor cells. The nanomedicine around 100 nm shows high anticancer activity and much reduced side effects in a subcutaneous breast cancer model when compared with cisplatin. In addition, it shows high accumulation at osteolytic lesions, and efficiently inhibits tumor growth and tumor‐associated osteolysis in a bone metastatic breast cancer model. Here, a facile and efficient strategy to prepare carrier‐free nanomedicines with high anticancer drug loading, inherent bone targeting, and osteoclast inhibitory activities for cancer therapy is provided.

Targeted and intracellular delivery of protein therapeutics by a boronated polymer for the treatment of bone tumors

“…For example, bisphosphonate conjugated poly (lactide- co -glycolide) (PLGA) or poly (lactic acid) (PLA) nanoparticles were loaded with anticancer drugs for the treatment of metastatic bone tumors and osteosarcoma [ 5 ]. The natural compound phytic acid with six phosphonate groups were reacted with cisplatin to prepare bone-targeted nanomedicine for the treatment of bone metastatic cancer [ 6 ]. Bisphosphonate and peptide conjugated nanoparticles were also proposed to treat bone tumors via photothermal therapy [ 7 ].…”

One‐pot preparation of small lipid‐indocyanine green nanoparticles to induced intracellular oxidative/thermal stress damage for effective colorectal cancer therapy

“…The introduction of nanomedicine into cancer therapy has provided a new paradise for effective cancer treatment. In recent years, more and more nanomaterials have been proposed by scientist across the globe, which showed promising anticancer performance [1][2][3]. In the meantime, more and more commercially available formulations, such as liposomal doxorubicin [4], paclitaxel loaded albumin nanoparticles [5], have been applied as first line agents with the aid of different materials and obtaining promising benefits.…”

Self-Remedied Nanomedicine for Surmounting the Achilles’ Heel of Photodynamic Tumor Therapy

“…Furthermore, the downregulation of HIF-1α might sensitize tumors to PDT, thereby improving the therapeutic effect. − It is supposed that the combination of YC-1 with PDT would significantly elevate the antitumor efficiency by HIF-1α inhibition. In view of the fact that different therapeutic agents hold diverse physicochemical properties and pharmacokinetics, the construction of drug co-delivery systems might be an effective strategy to realize their combined effect. − However, most of the traditional carrier-assistant drug delivery systems have some inevitable deficiencies including complex components, tedious preparation processes, and low drug loading rates. , Moreover, the extra excipients may have the potential toxicity and induce adverse immune responses. − In this case, the emerging drug self-delivery systems (DSDSs), which consist of pure drugs without additional carriers, have suggested tremendous advantages and application potential in recent years. , Even so, it is still difficult to screen suitable drugs for preparing DSDSs and making them work in concert. Particularly, HIF-1α-inhibitor-based DSDSs have rarely been reported for enhanced PDT.…”